[Press release] Bioplus received export permission to India, the world’s second-largest population
Bioplus obtained permission for Dermal Filler in the Indian market with 1.3 billion people.
Recently, Bioplus has acquired an export license to India, a 1.3-billion-strong market that is emerging as a major player in the beauty market with the world’s 10th largest scale.
Bioplus has already set up a local branch in New Delhi since 2018 and has been working on licensing, which led to bearing fruit recently.
India has recently seen a growing increase of filler treatments among petit plastic surgery. In addition, the national image of Korea has been greatly improved due to the influence of the Korean Wave such as K-POP and Korean movies, and the recent response of COVID-19 has also increased the image of Korean products.
Bioplus has already passed ‘MDSAP’ screening, a single European EC-held and medical device screening program and through this, it exports directly and indirectly to a number of foreign countries with skin care markets such as South America, Australia, Europe, Southeast Asia, and Russia.
A company official said, “This is an opportunity to expand and diversify export channels to various countries, and we will strengthen our sales capabilities outside of India by utilizing our know-how and overseas distribution networks.”